Ascitic fluid cephalosporin concentrations: influence of protein binding and serum pharmacokinetics.

Antimicrobial Agents and Chemotherapy
D N GerdingE A Schierl

Abstract

Mongrel dogs with ascites created by inferior vena cava ligation were given cephalothin, cephaloridine, cefazolin, and cefamandole to evaluate the effect of protein binding and serum pharmacokinetics on the distribution of cephalosporins into ascitic fluid. Antibiotics were given intramuscularly (15 mg/kg) every 4 h for a total of eight doses. Antibiotic binding to dog serum and ascitic fluid was measured by ultracentrifugation. Binding of the cephalosporins to dog serum ranged from 31% for cephaloridine to 46% for cephalothin, considerably lower than human serum binding for cefazolin, cephalothin, and cefamandole. Antibiotic binding to ascitic fluid was only slightly lower than that to serum. Ascitic fluid antibiotic concentrations, which approached equilibrium at 16 to 28 h, were significantly higher for cefazolin and cephaloridine than for cephalothin and cefamandole. However, serum concentrations were also higher for cefazolin and cephaloridine, and percent penetration (ratio of serum peak to ascites peak x 100) was not statistically different among the four drugs. Binding of these cephalosporins to extravascular fluid protein was an important factor that determined the total ascitic fluid antibiotic level achieved. A formu...Continue Reading

References

Apr 1, 1977·Antimicrobial Agents and Chemotherapy·C CarbonS Lamotte-Barrillon
Jun 1, 1977·Annals of Internal Medicine·D N GerdingE A Schierl
Jun 1, 1977·Antimicrobial Agents and Chemotherapy·D R Cole, J Pung
Jun 1, 1976·The Journal of Infectious Diseases·N G WatermanP A Barnwell
Oct 1, 1976·Antimicrobial Agents and Chemotherapy·N G WatermanL Scharfenberger
Nov 1, 1976·Antimicrobial Agents and Chemotherapy·D N GerdingW H Hall
Dec 1, 1976·Antimicrobial Agents and Chemotherapy·D N GerdingR E Manion
Oct 1, 1973·The Journal of Infectious Diseases·W M Kirby, C Regamey
Mar 1, 1974·Antimicrobial Agents and Chemotherapy·N WatermanM J Raff

❮ Previous
Next ❯

Citations

Mar 1, 1997·The Pediatric Infectious Disease Journal·F Scaglione
May 1, 1979·Antimicrobial Agents and Chemotherapy·I C Guerrero, R R MacGregor
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·L L Van EttaL R Peterson
Jan 1, 1985·Antimicrobial Agents and Chemotherapy·H YamadaK Iida
Jul 1, 1985·Antimicrobial Agents and Chemotherapy·M LeBelM G Bergeron
May 1, 1986·Antimicrobial Agents and Chemotherapy·G BenoniA Lechi
Oct 1, 1991·Antimicrobial Agents and Chemotherapy·D E NixJ J Schentag
Jan 1, 1992·Antimicrobial Agents and Chemotherapy·S TawaraS Goto
Jan 1, 1981·Biopharmaceutics & Drug Disposition·I Polacek
Oct 1, 1987·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section B, Microbiology·N Frimodt-MøllerV F Thomsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.